Articles

Feasibility of cell therapy in Multiple Sclerosis: A systematic review of 83 studies

Abstract

Multiple Sclerosis is an inflammatory disease of the central nervous system in which T cells experience a second phase of activation, which ultimately leads to axonal demyelination and neurological disability. The recent advances in stem cell therapies may serve as potential treatments for neurological disorders. There are broad types of stem cells such as neural, embryonic, mesenchymal and hematopoietic stem cells with unprecedented hope in treating many debilitating diseases. In this paper we will review the substantial literature regarding experimental and clinical use of these stem cells and possible mechanisms in the treatment of MS. These results may pave the road for the utilization of stem cells for the treatment of MS.

Al Jumah MA, Abumaree MH. The Immunomodulatory and Neuroprotective Effects of Mesenchymal Stem Cells (MSCs) in Experimental Autoimmune Encephalomyelitis (EAE): A Model of Multiple Sclerosis (MS). Int J Mol Sci. 2012; 13(7):9298-331.

Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med. [Review]. 2002;53:285-302.

Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol. [News]. 2001 Sep;2(9):762-4.

Chandran S, Compston A. Neural stem cells as a potential source of oligodendrocytes for myelin repair. J Neurol Sci. [Review]. 2005 Jun 15;233(1-2):179-81.

Keirstead HS. Stem cells for the treatment of myelin loss. Trends Neurosci. [Review]. 2005 Dec;28(12):677-83.

Silani V, Corbo M. Cell-Replacement Therapy with Stem Cells in Neurodegenerative Diseases. Current Neurovascular Research. 2004 Apr;1(3):283-9.

Su P, Loane C, Politis M. Review Paper, The Use of Stem Cells in the Treatment of Parkinson’s Disease. Insciences J. [Case Reports]. 2011 Feb;1(3):136-56.

Pluchino S, Martino G. The therapeutic plasticity of neural stem/precursor cells in multiple sclerosis. J Neurol Sci. [Research Support, Non-U.S. Gov't Review]. 2008 Feb 15;265(1-2):105-10.

Einstein O, Ben-Hur T. The changing face of neural stem cell therapy in neurologic diseases. Arch Neurol. [Review]. 2008 Apr;65(4):452-6.

Brundin L, Brismar H, Danilov AI, Olsson T, Johansson CB. Neural stem cells: a potential source for remyelination in neuroinflammatory disease. Brain Pathol. [Comparative Study Research Support, Non-U.S. Gov't]. 2003 Jul;13(3):322-8.

Nait-Oumesmar B, Picard-Riera N, Kerninon C, Decker L, Seilhean D, Hoglinger GU, et al. Activation of the subventricular zone in multiple sclerosis: evidence for early glial progenitors. Proc Natl Acad Sci U S A. [Research Support, Non-U.S. Gov't]. 2007 Mar 13;104(11):4694-9.

Einstein O, Grigoriadis N, Mizrachi-Kol R, Reinhartz E, Polyzoidou E, Lavon I, et al. Transplanted neural precursor cells reduce brain inflammation to attenuate chronic experimental autoimmune encephalomyelitis. Exp Neurol. [Comparative Study Research Support, Non-U.S. Gov't]. 2006 Apr;198(2):275-84.

Ben-Hur T, van Heeswijk RB, Einstein O, Aharonowiz M, Xue R, Frost EE, et al. Serial in vivo MR tracking of magnetically labeled neural spheres transplanted in chronic EAE mice. Magn Reson Med. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2007 Jan;57(1):164-71.

Ben-Hur T, Einstein O, Mizrachi-Kol R, Ben-Menachem O, Reinhartz E, Karussis D, et al. Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis. Glia. [Research Support, Non-U.S. Gov't]. 2003 Jan;41(1):73-80.

Weiss S, Dunne C, Hewson J, Wohl C, Wheatley M, Peterson AC, et al. Multipotent CNS stem cells are present in the adult mammalian spinal cord and ventricular neuroaxis. J Neurosci. [Research Support, Non-U.S. Gov't]. 1996 Dec 1;16(23):7599-609.

Garzon-Muvdi T, Quinones-Hinojosa A. Neural stem cell niches and homing: recruitment and integration into functional tissues. Ilar J. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. 2009;51(1):3-23.

Einstein O, Fainstein N, Vaknin I, Mizrachi-Kol R, Reihartz E, Grigoriadis N, et al. Neural precursors attenuate autoimmune encephalomyelitis by peripheral immunosuppression. Ann Neurol. [Research Support, Non-U.S. Gov't]. 2007 Mar;61(3):209-18.

Ben-Hur T. Immunomodulation by neural stem cells. J Neurol Sci. [Review]. 2008 Feb 15;265(1-2):102-4.

Pluchino S, Gritti A, Blezer E, Amadio S, Brambilla E, Borsellino G, et al. Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates. Ann Neurol. [Research Support, Non-U.S. Gov't]. 2009 Sep;66(3):343-54.

Quesenberry PJ, Dooner G, Colvin G, Abedi M. Stem cell biology and the plasticity polemic. Exp Hematol. [Research Support, U.S. Gov't, P.H.S. Review]. 2005 Apr;33(4):389-94.

Lindvall O, Kokaia Z. Stem cells for the treatment of neurological disorders. Nature. [Review]. 2006 Jun 29;441(7097):1094-6.

Yandava BD, Billinghurst LL, Snyder EY. "Global" cell replacement is feasible via neural stem cell transplantation: evidence from the dysmyelinated shiverer mouse brain. Proc Natl Acad Sci U S A. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 1999 Jun 8;96(12):7029-34.

Hammang JP, Archer DR, Duncan ID. Myelination following transplantation of EGF-responsive neural stem cells into a myelin-deficient environment. Exp Neurol. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 1997 Sep;147(1):84-95.

Milward EA, Lundberg CG, Ge B, Lipsitz D, Zhao M, Duncan ID. Isolation and transplantation of multipotential populations of epidermal growth factor-responsive, neural progenitor cells from the canine brain. J Neurosci Res. [Research Support, Non-U.S. Gov't]. 1997 Dec 1;50(5):862-71.

Kohama I, Lankford KL, Preiningerova J, White FA, Vollmer TL, Kocsis JD. Transplantation of cryopreserved adult human Schwann cells enhances axonal conduction in demyelinated spinal cord. J Neurosci. [In Vitro Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.]. 2001 Feb 1;21(3):944-50.

Barnett SC, Alexander CL, Iwashita Y, Gilson JM, Crowther J, Clark L, et al. Identification of a human olfactory ensheathing cell that can effect transplant-mediated remyelination of demyelinated CNS axons. Brain. [Research Support, Non-U.S. Gov't]. 2000 Aug;123 ( Pt 8):1581-8.

Kato T, Honmou O, Uede T, Hashi K, Kocsis JD. Transplantation of human olfactory ensheathing cells elicits remyelination of demyelinated rat spinal cord. Glia. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 2000 May;30(3):209-18.

Imaizumi T, Lankford KL, Burton WV, Fodor WL, Kocsis JD. Xenotransplantation of transgenic pig olfactory ensheathing cells promotes axonal regeneration in rat spinal cord. Nat Biotechnol. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.]. 2000 Sep;18(9):949-53.

Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G, et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature. [Research Support, Non-U.S. Gov't]. 2003 Apr 17;422(6933):688-94.

Magalon K, Cantarella C, Monti G, Cayre M, Durbec P. Enriched environment promotes adult neural progenitor cell mobilization in mouse demyelination models. Eur J Neurosci. 2007 Feb;25(3):761-71.

Karussis D, Kassis I, Kurkalli BG, Slavin S. Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J Neurol Sci. [Review]. 2008 Feb 15;265(1-2):131-5.

Zhang J, Li Y, Chen J, Cui Y, Lu M, Elias SB, et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 2005 Sep;195(1):16-26.

Pluchino S, Zanotti L, Brambilla E, Rovere-Querini P, Capobianco A, Alfaro-Cervello C, et al. Immune regulatory neural stem/precursor cells protect from central nervous system autoimmunity by restraining dendritic cell function. PLoS One. [Research Support, Non-U.S. Gov't]. 2009;4(6):e5959.

Makar TK, Trisler D, Sura KT, Sultana S, Patel N, Bever CT. Brain derived neurotrophic factor treatment reduces inflammation and apoptosis in experimental allergic encephalomyelitis. J Neurol Sci. [Research Support, U.S. Gov't, Non-P.H.S.]. 2008 Jul 15;270(1-2):70-6.

Portmann-Lanz CB, Schoeberlein A, Portmann R, Mohr S, Rollini P, Sager R, et al. Turning placenta into brain: placental mesenchymal stem cells differentiate into neurons and oligodendrocytes. Am J Obstet Gynecol. [Research Support, Non-U.S. Gov't]. 2010 Mar;202(3):294 e1- e11.

Lue J, Lin G, Ning H, Xiong A, Lin CS, Glenn JS. Transdifferentiation of adipose-derived stem cells into hepatocytes: a new approach. Liver Int. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2010 Jul;30(6):913-22.

Zhang Q, Shi S, Liu Y, Uyanne J, Shi Y, Le AD. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2009 Dec 15;183(12):7787-98.

najmadin Saki, Saeid Abroun, Majid Farshdusti Hagh, Farahnaz Asgharei. Neoplastic Bone Marrow Niche: Hematopoietic And Mesenchymal Stem Sells. Cell Journal (Yakhteh). 2011;13(3):131-6.

Jackson WM, Nesti LJ, Tuan RS. Potential therapeutic applications of muscle-derived mesenchymal stem and progenitor cells. Expert Opin Biol Ther. [Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Review]. 2010 Apr;10(4):505-17.

Dehghani Fard A., Saki N., Ahmadvand M., Mahmoodinia Maymand M., Mosahebi Mohammadi M., et al. Mesenchymal stem cell; biology, application and its role in regenerative medicine. Sci J Blood Transfus Organ. 2012;8(4):306-20

Krampera M, Sartoris S, Liotta F, Pasini A, Angeli R, Cosmi L, et al. Immune regulation by mesenchymal stem cells derived from adult spleen and thymus. Stem Cells Dev. [Research Support, Non-U.S. Gov't]. 2007 Oct;16(5):797-810.

Reger RL, Tucker AH, Wolfe MR. Differentiation and characterization of human MSCs. Methods Mol Biol. 2008;449:93-107.

Delorme B, Nivet E, Gaillard J, Haupl T, Ringe J, Deveze A, et al. The human nose harbors a niche of olfactory ectomesenchymal stem cells displaying neurogenic and osteogenic properties. Stem Cells Dev. [Research Support, Non-U.S. Gov't]. 2010 Jun;19(6):853-66.

in 't Anker PS, Noort WA, Scherjon SA, Kleijburg-van der Keur C, Kruisselbrink AB, van Bezooijen RL, et al. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica. 2003 Aug;88(8):845-52.

Dazzi F, Krampera M. Mesenchymal stem cells and autoimmune diseases. Best Pract Res Clin Haematol. [Review]. 2011 Mar;24(1):49-57.

Slavin S, Kurkalli BG, Karussis D. The potential use of adult stem cells for the treatment of multiple sclerosis and other neurodegenerative disorders. Clin Neurol Neurosurg. [Review]. 2008 Nov;110(9):943-6.

Gregory CA, Prockop DJ, Spees JL. Non-hematopoietic bone marrow stem cells: molecular control of expansion and differentiation. Exp Cell Res. [Review]. 2005 Jun 10;306(2):330-5.

Harris VK, Yan QJ, Vyshkina T, Sahabi S, Liu X, Sadiq SA. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis. J Neurol Sci. 2011 Sep 28.

Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. [Clinical Trial, Phase I Clinical Trial, Phase II Research Support, Non-U.S. Gov't]. 2010 Oct;67(10):1187-94.

Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A, et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol. [Clinical Trial, Phase I Comparative Study Research Support, Non-U.S. Gov't]. 2010 Oct 8;227(1-2):185-9.

Zhang YJ, Zhang W, Lin CG, Ding Y, Huang SF, Wu JL, et al. Neurotrophin-3 gene modified mesenchymal stem cells promote remyelination and functional recovery in the demyelinated spinal cord of rats. J Neurol Sci. 2011 Oct 12.

Frohman EM, Racke MK, Raine CS. Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. 2006 Mar 2;354(9):942-55.

Tabatabai G, Bahr O, Mohle R, Eyupoglu IY, Boehmler AM, Wischhusen J, et al. Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells. Brain. [Research Support, Non-U.S. Gov't]. 2005 Sep;128(Pt 9):2200-11.

McCormack PL, Scott LJ. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis. CNS Drugs. [Review]. 2004;18(8):521-46.

van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol. [Multicenter Study]. 2011 Apr 1;29(10):1342-8.

Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant. 1997 Oct;20(8):631-8.

Burt RK, Traynor AE, Cohen B, Karlin KH, Davis FA, Stefoski D, et al. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant. [Clinical Trial]. 1998 Mar;21(6):537-41.

Kewalramani T, Nimer SD, Zelenetz AD, Malhotra S, Qin J, Yahalom J, et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 2003 Oct;32(7):673-9.

Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. [Research Support, Non-U.S. Gov't]. 2010 Dec 2;116(23):4934-7.

Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. [Review]. 2003;14 Suppl 1:i5-10.

van Bekkum DW. Stem cell transplantation for autoimmune disorders. Preclinical experiments. Best Pract Res Clin Haematol. [Review]. 2004 Jun;17(2):201-22.

van Gelder M, van Bekkum DW. Treatment of relapsing experimental autoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation from a resistant strain. Bone Marrow Transplant. [Research Support, Non-U.S. Gov't]. 1995 Sep;16(3):343-51.

van Gelder M, Kinwel-Bohre EP, van Bekkum DW. Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT. Bone Marrow Transplant. [Research Support, Non-U.S. Gov't]. 1993 Mar;11(3):233-41.

van Gelder M, van Bekkum DW. Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation. Bone Marrow Transplant. [Research Support, Non-U.S. Gov't]. 1996 Dec;18(6):1029-34.

Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H. TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med. [Research Support, Non-U.S. Gov't]. 2007 Apr;4(4):e124.

Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 1988 Jan 15;239(4837):290-2.

Priller J, Flugel A, Wehner T, Boentert M, Haas CA, Prinz M, et al. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat Med. [Research Support, Non-U.S. Gov't]. 2001 Dec;7(12):1356-61.

Simard AR, Rivest S. Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. Faseb J. [Research Support, Non-U.S. Gov't]. 2004 Jun;18(9):998-1000.

Flugel A, Bradl M, Kreutzberg GW, Graeber MB. Transformation of donor-derived bone marrow precursors into host microglia during autoimmune CNS inflammation and during the retrograde response to axotomy. J Neurosci Res. [Research Support, Non-U.S. Gov't]. 2001 Oct 1;66(1):74-82.

Bechmann I, Goldmann J, Kovac AD, Kwidzinski E, Simburger E, Naftolin F, et al. Circulating monocytic cells infiltrate layers of anterograde axonal degeneration where they transform into microglia. Faseb J. [Research Support, Non-U.S. Gov't]. 2005 Apr;19(6):647-9.

Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature. [Letter]. 1997 Nov 27;390(6658):350-1.

Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol. [Research Support, Non-U.S. Gov't Review]. 2002 Dec;2(12):965-75.

Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. 2005 Dec;6(12):1191-7.

Xu J, Ji BX, Su L, Dong HQ, Sun XJ, Liu CY. Clinical outcomes after autologous haematopoietic stem cell transplantation in patients with progressive multiple sclerosis. Chin Med J (Engl). [Research Support, Non-U.S. Gov't]. 2006 Nov 20;119(22):1851-5.

Tyndall A, Matucci-Cerinic M. Haematopoietic stem cell transplantation for the treatment of systemic sclerosis and other autoimmune disorders. Expert Opin Biol Ther. [Review]. 2003 Oct;3(7):1041-9.

Saiz A, Carreras E, Berenguer J, Yague J, Martinez C, Marin P, et al. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. Neurology. [Research Support, Non-U.S. Gov't]. 2001 Apr 24;56(8):1084-9.

Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kozak T, Havrdova E, et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol. [Clinical Trial Clinical Trial, Phase I Clinical Trial, Phase II Multicenter Study Research Support, Non-U.S. Gov't]. 2002 Aug;249(8):1088-97.

Weissman IL, Shizuru JA. The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. Blood. [Research Support, N.I.H., Extramural Review]. 2008 Nov 1;112(9):3543-53.

Mandalfino P, Rice G, Smith A, Klein JL, Rystedt L, Ebers GC. Bone marrow transplantation in multiple sclerosis. J Neurol. 2000 Sep;247(9):691-5.

Lu JQ, Storek J, Metz L, Yong VW, Stevens AM, Nash RA, et al. Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation. Arch Neurol. [Case Reports Research Support, Non-U.S. Gov't]. 2009 Jan;66(1):116-20.

Gualandi F, Bruno B, Van Lint MT, Luchetti S, Uccelli A, Capello E, et al. Autologous stem cell transplantation for severe autoimmune diseases: a 10-year experience. Ann N Y Acad Sci. 2007 Sep;1110:455-64.

Denham M, Cole TJ, Mollard R. Embryonic stem cells form glandular structures and express surfactant protein C following culture with dissociated fetal respiratory tissue. Am J Physiol Lung Cell Mol Physiol. [Research Support, Non-U.S. Gov't]. 2006 Jun;290(6):L1210-5.

Conley BJ, Trounson AO, Mollard R. Human embryonic stem cells form embryoid bodies containing visceral endoderm-like derivatives. Fetal Diagn Ther. [Research Support, Non-U.S. Gov't]. 2004 May-Jun;19(3):218-23.

Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. [Research Support, Non-U.S. Gov't]. 1998 Nov 6;282(5391):1145-7.

Brustle O, Jones KN, Learish RD, Karram K, Choudhary K, Wiestler OD, et al. Embryonic stem cell-derived glial precursors: a source of myelinating transplants. Science. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 1999 Jul 30;285(5428):754-6.

Liu S, Qu Y, Stewart TJ, Howard MJ, Chakrabortty S, Holekamp TF, et al. Embryonic stem cells differentiate into oligodendrocytes and myelinate in culture and after spinal cord transplantation. Proc Natl Acad Sci U S A. [Research Support, Non-U.S.

Gov't Research Support, U.S. Gov't, P.H.S.]. 2000 May 23;97(11):6126-31.

Billon N, Jolicoeur C, Ying QL, Smith A, Raff M. Normal timing of oligodendrocyte development from genetically engineered, lineage-selectable mouse ES cells. J Cell Sci. [Research Support, Non-U.S. Gov't]. 2002 Sep 15;115(Pt 18):3657-65.

Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol. 2000 Apr;18(4):399-404.

Reubinoff BE, Itsykson P, Turetsky T, Pera MF, Reinhartz E, Itzik A, et al. Neural progenitors from human embryonic stem cells. Nat Biotechnol. [Research Support, Non-U.S. Gov't]. 2001 Dec;19(12):1134-40.

Zhang SC, Wernig M, Duncan ID, Brustle O, Thomson JA. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol. [Research Support, Non-U.S. Gov't]. 2001 Dec;19(12):1129-33.

Li XJ, Hu BY, Jones SA, Zhang YS, Lavaute T, Du ZW, et al. Directed differentiation of ventral spinal progenitors and motor neurons from human embryonic stem cells by small molecules. Stem Cells. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2008 Apr;26(4):886-93.

Martinat C, Bacci JJ, Leete T, Kim J, Vanti WB, Newman AH, et al. Cooperative transcription activation by Nurr1 and Pitx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype. Proc Natl Acad Sci U S A. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2006 Feb 21;103(8):2874-9.

Pomp O, Brokhman I, Ben-Dor I, Reubinoff B, Goldstein RS. Generation of peripheral sensory and sympathetic neurons and neural crest cells from human embryonic stem cells. Stem Cells. [Research Support, Non-U.S. Gov't]. 2005 Aug;23(7):923-30.

Lee G, Kim H, Elkabetz Y, Al Shamy G, Panagiotakos G, Barberi T, et al. Isolation and directed differentiation of neural crest stem cells derived from human embryonic stem cells. Nat Biotechnol. [Research Support, Non-U.S. Gov't]. 2007 Dec;25(12):1468-75.

Izrael M, Zhang P, Kaufman R, Shinder V, Ella R, Amit M, et al. Human oligodendrocytes derived from embryonic stem cells: Effect of noggin on phenotypic differentiation in vitro and on myelination in vivo. Mol Cell Neurosci. [Research Support, Non-U.S. Gov't]. 2007 Mar;34(3):310-23.

Hu BY, Du ZW, Li XJ, Ayala M, Zhang SC. Human oligodendrocytes from embryonic stem cells: conserved SHH signaling networks and divergent FGF effects. Development. [Research Support, N.I.H., Extramural]. 2009 May;136(9):1443-52.

Nistor GI, Totoiu MO, Haque N, Carpenter MK, Keirstead HS. Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation. Glia. [Research Support, Non-U.S. Gov't]. 2005 Feb;49(3):385-96.

Hentze H, Graichen R, Colman A. Cell therapy and the safety of embryonic stem cell-derived grafts. Trends Biotechnol. [Review]. 2007 Jan;25(1):24-32.

Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, Roy M, Quinones-Hinojosa A, VandenBerg S, et al. PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2006 Jul 20;51(2):187-99.

Aharonowiz M, Einstein O, Fainstein N, Lassmann H, Reubinoff B, Ben-Hur T. Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis. PLoS One. [Research Support, Non-U.S. Gov't]. 2008;3(9):e3145.

Heffernan C, Sumer H, Guillemin GJ, Manuelpillai U, Verma PJ. Design and screening of a glial cell-specific, cell penetrating peptide for therapeutic applications in multiple sclerosis. PLoS One. [Research Support, Non-U.S. Gov't]. 2012;7(9):e45501.

Payne NL, Sun G, Herszfeld D, Tat-Goh PA, Verma PJ, Parkington HC, et al. Comparative study on the therapeutic potential of neurally differentiated stem cells in a mouse model of multiple sclerosis. PLoS One. [Research Support, Non-U.S. Gov't]. 2012;7(4):e35093.

Song B, Sun G, Herszfeld D, Sylvain A, Campanale NV, Hirst CE, et al. Neural differentiation of patient specific iPS cells as a novel approach to study the pathophysiology of multiple sclerosis. Stem Cell Res. [Research Support, Non-U.S. Gov't]. 2012 Mar;8(2):259-73.

Rasmussen S, Imitola J, Ayuso-Sacido A, Wang Y, Starossom SC, Kivisäkk P, et al. Reversible neural stem cell niche dysfunction in a model of multiple sclerosis. Ann Neurol. 2011;69(5):878-91.

Huang JK, Franklin RJ. Regenerative medicine in multiple sclerosis: identifying pharmacological targets of adult neural stem cell differentiation. Neurochem Int. [Review]. 2011 Sep;59(3):329-32.

Giannakopoulou A, Grigoriadis N, Polyzoidou E, Touloumi O, Michaloudi E, Papadopoulos GC. Inflammatory changes induced by transplanted neural precursor cells in a multiple sclerosis model. Neuroreport. [Research Support, Non-U.S. Gov't]. 2011 Jan 26;22(2):68-72.

Carbajal KS, Weinger JG, Whitman LM, Schaumburg CS, Lane TE. Surgical transplantation of mouse neural stem cells into the spinal cords of mice infected with neurotropic mouse hepatitis virus. J Vis Exp. [Video-Audio Media]. 2011(53):e2834.

Yip S, Aboody KS, Burns M, Imitola J, Boockvar JA, Allport J, et al. Neural stem cell biology may be well suited for improving brain tumor therapies. Cancer J. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.Review]. 2003 May-Jun;9(3):189-204.

Bonab MM, Sahraian MA, Aghsaie A, Karvigh SA, Hosseinian SM, Nikbin B, et al. Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study. Curr Stem Cell Res Ther. 2012 Nov 1;7(6):407-14.

Payne NL, Sun G, McDonald C, Layton D, Moussa L, Emerson-Webber A, et al. Distinct immunomodulatory and migratory mechanisms underpin the therapeutic potential of human mesenchymal stem cells in autoimmune demyelination. Cell Transplant. 2012 Oct 4. DOI:10.3727/096368912X657620. [Epub ahead of print]

Cobo M, Anderson P, Benabdellah K, Toscano MG, Munoz P, Garcia-Perez A, et al. Mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis. Cell Transplant. 2012 Oct 2. [Epub ahead of print] PubMed PMID: 23031550.

Al Jumah MA, Abumaree MH. The Immunomodulatory and Neuroprotective Effects of Mesenchymal Stem Cells (MSCs) in Experimental Autoimmune Encephalomyelitis (EAE): A Model of Multiple Sclerosis (MS). Int J Mol Sci. 2012;13(7):9298-331.

Fisher-Shoval Y, Barhum Y, Sadan O, Yust-Katz S, Ben-Zur T, Lev N, et al. Transplantation of placenta-derived mesenchymal stem cells in the EAE mouse model of MS. J Mol Neurosci. 2012 Sep;48(1):176-84.

Bai L, Lennon DP, Caplan AI, DeChant A, Hecker J, Kranso J, et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat Neurosci. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2012 Jun;15(6):862-70.

Payne NL, Dantanarayana A, Sun G, Moussa L, Caine S, McDonald C, et al. Early intervention with gene-modified mesenchymal stem cells overexpressing interleukin-4 enhances anti-inflammatory responses and functional recovery in experimental autoimmune demyelination. Cell Adh Migr. [Research Support, Non-U.S. Gov't]. 2012 May-Jun;6(3):179-89.

Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. [Clinical Trial, Phase II]. 2012 Feb;11(2):150-6.

Zhang YJ, Zhang W, Lin CG, Ding Y, Huang SF, Wu JL, et al. Neurotrophin-3 gene modified mesenchymal stem cells promote remyelination and functional recovery in the demyelinated spinal cord of rats. J Neurol Sci. [Comparative Study Research Support, Non-U.S. Gov't]. 2012 Feb 15;313(1-2):64-74.

Harris VK, Faroqui R, Vyshkina T, Sadiq SA. Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis. Stem Cells Transl Med. [Research Support, Non-U.S. Gov't]. 2012 Jul;1(7):536-47.

Odinak MM, Bisaga GN, Novitskii AV, Tyrenko VV, Fominykh MS, Bilibina AA, et al. [Transplantation of mesenchymal stem cells in multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsak. [Clinical Trial]. 2011;111(2 Pt 2):72-6.

Mohajeri M, Farazmand A, Mohyeddin Bonab M, Nikbin B, Minagar A. FOXP3 gene expression in multiple sclerosis patients pre- and post mesenchymal stem cell therapy. Iran J Allergy Asthma Immunol. 2011 10(3):155-61.

Grigoriadis N, Lourbopoulos A, Lagoudaki R, Frischer JM, Polyzoidou E, Touloumi O, et al. Variable behavior and complications of autologous bone marrow mesenchymal stem cells transplanted in experimental autoimmune encephalomyelitis. Exp Neurol. [Research Support, Non-U.S. Gov't]. 2011 Jul;230(1):78-89.

Cristofanilli M, Harris VK, Zigelbaum A, Goossens AM, Lu A, Rosenthal H, et al. Mesenchymal stem cells enhance the engraftment and myelinating ability of allogeneic oligodendrocyte progenitors in dysmyelinated mice. Stem Cells Dev. [Research Support, Non-U.S. Gov't]. 2011 Dec;20(12):2065-76.

Darlington PJ, Boivin MN, Renoux C, Francois M, Galipeau J, Freedman MS, et al. Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. Annals of neurology. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2010 Oct;68(4):540-5.

Rice CM, Scolding NJ. Adult human mesenchymal cells proliferate and migrate in response to chemokines expressed in demyelination. Cell Adh Migr. [Research Support, Non-U.S. Gov't]. 2010 Apr-Jun;4(2):235-40.

Kemp K, Gray E, Mallam E, Scolding N, Wilkins A. Inflammatory cytokine induced regulation of superoxide dismutase 3 expression by human mesenchymal stem cells. Stem Cell Rev. [Research Support, Non-U.S. Gov't]. 2010 Dec;6(4):548-59.

Barhum Y, Gai-Castro S, Bahat-Stromza M, Barzilay R, Melamed E, Offen D. Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosis. J Mol Neurosci. [Research Support, Non-U.S. Gov't]. 2010 May;41(1):129-37.

Constantin G, Marconi S, Rossi B, Angiari S, Calderan L, Anghileri E, et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells. 2009 Oct;27(10):2624-35.

Liang J, Zhang H, Hua B, Wang H, Wang J, Han Z, et al. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult Scler. 2009 May;15(5):644-6.

Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia. 2009 Aug 15;57(11):1192-203.

Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J, Alimoghaddom K, Talebian F, Hooshmand F, et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol. 2007;4(1):50-7.

Shevchenko JL, Kuznetsov AN, Ionova TI, Melnichenko VY, Fedorenko DA, Kartashov AV, et al. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. Exp Hematol. [Clinical Trial, Phase II]. 2012 Nov;40(11):892-8.

Rabusin M, Snowden JA, Veys P, Quartier P, Dalle JH, Dhooge C, et al. Long-Term Outcomes of Hematopoietic Stem Cell Transplantation for Severe Treatment-Resistant Autoimmune Cytopenia in Children. Biol Blood Marrow Transplant. 2012 Dec 16. doi:pii: S1083-8791(12)01144-5.

Lutterotti A, Jelcic I, Schulze C, Schippling S, Breiden P, Mazzanti B, et al. No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients. Mult Scler. 2012 Aug;18(8):1188-92.

Atkins HL, Muraro PA, van Laar JM, Pavletic SZ. Autologous hematopoietic stem cell transplantation for autoimmune disease--is it now ready for prime time? Biol Blood Marrow Transplant. [Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Review]. 2012 Jan;18(1 Suppl):S177-83.

Chen B, Zhou M, Ouyang J, Zhou R, Xu J, Zhang Q, et al. Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China. Neurol Sci. 2012;33(4)::881-6.

Mancardi GL, Sormani MP, Di Gioia M, Vuolo L, Gualandi F, Amato MP, et al. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler. [Multicenter Study Research Support, Non-U.S. Gov't]. 2012 Jun;18(6):835-42.

Capobianco M, Motuzova Y, Frau J, Cocco E, Mamusa E, Marrosu MG, et al. Natalizumab in aggressive multiple sclerosis after haematopoietic stem cell transplantation. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2012 Aug;33(4):863-7.

Fassas A, Kimiskidis VK, Sakellari I, Kapinas K, Anagnostopoulos A, Tsimourtou V, et al. Long-term results of stem cell transplantation for MS: a single-center experience. Neurology. [Clinical Trial Research Support, Non-U.S. Gov't]. 2011 Mar 22;76(12):1066-70.

Reston JT, Uhl S, Treadwell JR, Nash RA, Schoelles K. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. Mult Scler. [Meta-Analysis Research Support, Non-U.S. Gov't Review]. 2011 Feb;17(2):204-13.

Xu J, Ji BX, Su L, Dong HQ, Sun WL, Wan SG, et al. Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population. Ann Hematol. [Clinical Trial Research Support, Non-U.S. Gov't]. 2011 Mar;90(3):343-8.

Guimaraes FA, Oliveira-Cardoso EA, Mastropietro AP, Voltarelli JC, Santos MA. Impact of autologous hematopoetic stem cell transplantation on the quality of life of patients with multiple sclerosis. Arq Neuropsiquiatr. [Evaluation Studies Research Support, Non-U.S. Gov't]. 2010 Aug;68(4):522-7.

Lu JQ, Joseph JT, Nash RA, Storek J, Stevens AM, Metz LM, et al. Neuroinflammation and demyelination in multiple sclerosis after allogeneic hematopoietic stem cell transplantation. Arch Neurol. [Research Support, Non-U.S. Gov't]. 2010 Jun;67(6):716-22.

Krasulova E, Trneny M, Kozak T, Vackova B, Pohlreich D, Kemlink D, et al. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult Scler. [Research Support, Non-U.S. Gov't]. 2010 Jun;16(6):685-93.

Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro PA, Mancardi GL, et al. Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis. Bone Marrow Transplant. [Comparative Study]. 2010 Jun;45(6):1014-21.

Rogojan C, Frederiksen JL. Hematopoietic stem cell transplantation in multiple sclerosis. Acta Neurol Scand. [Review]. 2009 Dec;120(6):371-82.

Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. [Clinical Trial, Phase I Clinical Trial, Phase II Research Support, Non-U.S. Gov't]. 2009 Mar;8(3):244-53.

Fassas A, Mancardi GL. Autologous hemopoietic stem cell transplantation for multiple sclerosis: is it worthwile? Autoimmunity. [Review]. 2008 Dec;41(8):601-10.

Fagius J, Lundgren J, Oberg G. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult Scler. [Clinical Trial]. 2009 Feb;15(2):229-37.

Saiz A, Blanco Y, Berenguer J, Gomez-Choco M, Carreras E, Arbizu T, et al. [Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis]. Neurologia. 2008 Sep;23(7):405-7.

Shevchenko YL, Novik AA, Kuznetsov AN, Afanasiev BV, Lisukov IA, Kozlov VA, et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol. [Clinical Trial, Phase II Multicenter Study]. 2008 Aug;36(8):922-8.

Rocca MA, Mondria T, Valsasina P, Sormani MP, Flach ZH, Te Boekhorst PA, et al. A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis. AJNR Am J Neuroradiol. [Clinical Trial]. 2007 Oct;28(9):1659-61.

Portaccio E, Amato MP, Siracusa G, Pagliai F, Sorbi S, Guidi S, et al. Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases. Mult Scler. [Case Reports]. 2007 Jun;13(5):676-8.

Roccatagliata L, Rocca M, Valsasina P, Bonzano L, Sormani M, Saccardi R, et al. Italian GITMO-NEURO Intergroup on Autologous Stem Cell Transplantation. The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Mult Scler. 2007 13(8):1068-70.

Metz I, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman MS, et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain. [Research Support, Non-U.S. Gov't]. 2007 May;130(Pt 5):1254-62.

Loh Y, Oyama Y, Statkute L, Quigley K, Yaung K, Gonda E, et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood. 2007 Mar 15;109(6):2643-548.

Su L, Xu J, Ji BX, Wan SG, Lu CY, Dong HQ, et al. Autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Int J Hematol. 2006 Oct;84(3):276-81.

Ni XS, Ouyang J, Zhu WH, Wang C, Chen B. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin Transplant. [Research Support, Non-U.S. Gov't]. 2006 Jul-Aug;20(4):485-9.

Daumer M, Griffith LM, Meister W, Nash RA, Wolinsky JS. Survival, and time to an advanced disease state or progression, of untreated patients with moderately severe multiple sclerosis in a multicenter observational database: relevance for design of a clinical trial for high dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation. Mult Scler. [Multicenter Study Research Support, N.I.H., Extramural]. 2006 Apr;12(2):174-9.

Papadaki HA, Tsagournisakis M, Mastorodemos V, Pontikoglou C, Damianaki A, Pyrovolaki K, et al. Normal bone marrow hematopoietic stem cell reserves and normal stromal cell function support the use of autologous stem cell transplantation in patients with multiple sclerosis. Bone Marrow Transplant. [Research Support, Non-U.S. Gov't]. 2005 Dec;36(12):1053-63.

Blanco Y, Saiz A, Costa M, Torres-Peraza JF, Carreras E, Alberch J, et al. Evolution of brain-derived neurotrophic factor levels after autologous hematopietic stem cell transplantation in multiple sclerosis. Neurosci Lett. [Clinical Trial Comparative Study Research Support, Non-U.S. Gov't]. 2005 May 20-27;380(1-2):122-6.

Blanco Y, Saiz A, Carreras E, Graus F. Autologous haematopoietic-stem-cell transplantation for multiple sclerosis. Lancet Neurol. [Research Support, Non-U.S. Gov't Review]. 2005 Jan;4(1):54-63.

Saccardi R, Tyndall A, Coghlan G, Denton C, Edan G, Emdin M, et al. Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant. [Consensus Development Conference Research Support, Non-U.S. Gov't]. 2004 Nov;34(10):877-81.

Blanco Y, Saiz A, Carreras E, Graus F. Changes of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) after autologous hematopoietic stem cell transplantation in multiple sclerosis. J Neuroimmunol. [Comparative Study]. 2004 Aug;153(1-2):190-4.

Healey KM, Pavletic SZ, Al-Omaishi J, Leuschen MP, Pirruccello SJ, Filipi ML, et al. Discordant functional and inflammatory parameters in multiple sclerosis patients after autologous haematopoietic stem cell transplantation. Mult Scler. [Clinical Trial Research Support, Non-U.S. Gov't]. 2004 Jun;10(3):284-9.

Inglese M, Mancardi GL, Pagani E, Rocca MA, Murialdo A, Saccardi R, et al. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J Neurol Neurosurg Psychiatry. [Clinical Trial Clinical Trial, Phase I Clinical Trial, Phase II Research Support, Non-U.S. Gov't]. 2004 Apr;75(4):643-4.

Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G, et al. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 2004 May;127(Pt 5):996-1008.

Saiz A, Blanco Y, Carreras E, Berenguer J, Rovira M, Pujol T, et al. Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology. [Research Support, Non-U.S. Gov't]. 2004 Jan 27;62(2):282-4.

Saccardi R, Mancardi GL, Solari A, Bosi A, Bruzzi P, Di Bartolomeo P, et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood. [Multicenter Study Research Support, Non-U.S. Gov't]. 2005 Mar 15;105(6):2601-7.

Burt RK, Cohen BA, Russell E, Spero K, Joshi A, Oyama Y, et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood. [Clinical Trial Clinical Trial, Phase I Clinical Trial, Phase II]. 2003 Oct 1;102(7):2373-8.

Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood. [Clinical Trial Multicenter Study Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.]. 2003 Oct 1;102(7):2364-72.

Carreras E, Saiz A, Marin P, Martinez C, Rovira M, Villamor N, et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica. [Clinical Trial Research Support, Non-U.S. Gov't]. 2003 Mar;88(3):306-14.

Rossiev VA, Makarov SV, Aleksandrova I, Dolgikh GT, Lipshina SR, Stukalova TA, et al. [Experience with high-dose immunosuppressive therapy followed by transplantation of autologous stem hematopoietic cells in patients with multiple sclerosis]. Ter Arkh. [Clinical Trial]. 2002;74(7):35-8.

Ouyang J, Ni X, Chen B. [A preliminary result of treatment of progressive multiple sclerosis with autologous peripheral blood stem cell transplantation in China]. Zhonghua Nei Ke Za Zhi. [Case Reports]. 2001 Aug;40(8):550-2.

Files
IssueVol 7, No 1 (2013) QRcode
SectionArticles
Keywords
Hematopoietic stem cells Human embryonic stem cells Mesenchymal stem cells Multiple sclerosis Neural stem cells Stem cells therapy
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Ardeshiry Lajimi A, Hagh MF, Saki N, Mortaz E, Soleimani M, Rahim F. Feasibility of cell therapy in Multiple Sclerosis: A systematic review of 83 studies. Int J Hematol Oncol Stem Cell Res. 1;7(1):13-30.